Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Controlled Human Infection With Intradermal BCG
NCT05820594Unknown
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bcg vaccine in Tuberculosis (TB), sponsored by Liverpool School of Tropical Medicine. Primary endpoint: Quantify BCG recovered from the intradermal BCG challenge site at Day 14. Status: unknown.
02
Drugs
bcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05820594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05820594.